Telbivudine versus lamivudine in patients with chronic hepatitis B

• المؤلفون الرئيسيون: Ching Lung Lai, Edward Gane, Yun Fan Liaw, Chao Wei Hsu, Satawat Thongsawat, Yuming Wang, Yagang Chen, E. Jenny Heathcote, Jens Rasenack, Natalie Bzowej, Nikolai V. Naoumov, Adrian M. Di Bisceglie, Stefan Zeuzem, Young Myoung Moon, Zachary Goodman, George Chao, Barbara Fielman Constance, Nathaniel A. Brown
• التنسيق: دورية
• منشور في: 2018
• الموضوعات: Medicine
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=37349120537&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/61227
• المؤسسة: Chiang Mai University

BACKGROUND: Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B. METHODS: In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamivudi...